Management of Tizanidine-Induced Transaminitis
Severity-Based Management Algorithm
- Discontinue tizanidine immediately in patients with Grade 1 Transaminitis (ALT/AST >ULN to 3× ULN) and monitor liver function tests 1-2 times weekly until normalization, as recommended by Praxis Medical Insights 1
- Discontinue tizanidine immediately in patients with Grade 2 Transaminitis (ALT/AST >3× to 5× ULN), increase monitoring frequency to every 3 days, and evaluate for concurrent hepatotoxic medications, as recommended by Praxis Medical Insights 1
- Discontinue tizanidine permanently in patients with Grade 3 Transaminitis (ALT/AST >5× to 20× ULN), obtain urgent hepatology consultation, and monitor for signs of acute liver failure, as recommended by Praxis Medical Insights 1
- Hospitalize patients with Grade 4 Transaminitis (ALT/AST >20× ULN) immediately, preferably at a liver center, and permanently discontinue tizanidine, as recommended by Praxis Medical Insights 1
Monitoring Requirements
- Repeat liver function tests within 2-4 weeks after discontinuation of tizanidine and continue monitoring every 2-4 weeks until complete normalization, as recommended by Praxis Medical Insights 1
- Reassess at 12 weeks to confirm sustained resolution of transaminitis, as recommended by Praxis Medical Insights 2
Alternative Muscle Relaxant Selection
- Consider Baclofen as the preferred alternative for spasticity management, though it requires careful dose titration and should never be abruptly discontinued due to risk of life-threatening withdrawal, as recommended by the Mayo Clinic 5
- Consider Cyclobenzaprine for musculoskeletal conditions, though it has anticholinergic effects and should be held on the day of any surgical procedure, as recommended by the Mayo Clinic 5
- Avoid carisoprodol due to its abuse potential and significant withdrawal risk, as recommended by the Mayo Clinic 5